Objectives: Vascular endothelial growth factor (VEGF) acts in angiogenesis and neuroprotection, although the beneficial effects on experimental ischemic stroke (IS) have not been replicated in clinical studies. We investigated serum VEGF (s-VEGF) in the acute stage (baseline) and 3 months post-stroke in relation to stroke severity and functional outcome.
| INTRODUC TI ON
Vascular endothelial growth factor (VEGF) is a 20-kDa homodimeric peptide hormone or growth factor that promotes angiogenesis, lymphangiogenesis, and vascular permeability (for review, see 1 ). In the brain parenchyma, VEGF is not only expressed in endothelial cells, but also in astrocytes and neurons (for review, see 2 ). Thus, VEGF and VEGF receptor (VEGF-R) isoforms are widely expressed in the brain and are upregulated in response to cerebral ischemia (for review, see 2 ). Although post-stroke increases in the brain levels of VEGF or VEGF-R suggests the importance of VEGF signaling in relation to stroke, these responses may be secondary to injury and not neuroprotective. In the case of VEGF administration, two opposite types of responses complicate the understanding of VEGF action after stroke. In experimental stroke, local administration of VEGF within the brain exerts neuroprotective and plasticity-promoting effects, 2 whereas systemic administration of VEGF reduces recovery. [2] [3] [4] [5] Thus, the actions of endogenous and exogenous VEGF might be different, and in addition, the mode of administration could influence the effects of VEGF in ischemic stroke (IS).
In patients with IS, in line with the experimental findings, endogenous serum VEGF (s-VEGF) has shown variable responses to IS, and the associations with functional outcomes have differed between studies. [6] [7] [8] [9] [10] [11] [12] [13] [14] These discrepancies may be attributable to the relatively small study cohorts with lower statistical power, biased selection of specific stroke types, or short follow-up periods. For example, s-VEGF was significantly increased in patients with acute IS (N = 29) at 0-7 days post-stroke compared to healthy controls without any clear day-to-day changes in s-VEGF. 6 A similar pattern of elevation of s-VEGF was shown in two relatively small studies that included both IS and hemorrhagic strokes (N = 52 and N = 33), with no association to improvement in the National Institutes of Health Stroke Scale (NIHSS) scores after 1 week, 12 or in the Stroke Impairment Assessment Set (SIAS) at discharge approximately 3 months poststroke. 13 In another study (N = 30), the s-VEGF levels appeared to be more dynamic, with a plateau phase until Day 7 after an initial increase on Day 1-3. 10 Interestingly, in a recent study (N = 83), high s-VEGF levels 7 days after IS correlated significantly with better functional outcome (mRS 0-2) after 3 months, 8 although it was not examined whether baseline stroke severity or IS subtype affected these associations. Similarly, although the absolute functional outcome levels were not presented, high s-VEGF levels at 24 hours post-stroke were independently associated with a more marked improvement in NIHSS scores up to 3 months in IS patients with large vessel disease or small vessel disease (N = 180). 15 This is in contrast to another report, in which high-level plasma VEGF was associated with a worse 3-month functional outcome in cardioembolic IS, but not in other IS etiologies (N = 171). 9 A similar association was found for 90-day s-VEGF and the radiologic appearance of small vessel disease burden in IS patients (N = 263) having undergone thrombolysis, whereas functional outcome was not reported. 14 This underlines that stroke subtype and potential biases in the selection of patients need to be taken into account when evaluating the importance of s-VEGF in IS.
In summary, the role of s-VEGF in human IS remains unclear and there are conflicting data in terms of the association with IS outcome as previous studies have been relatively small and only reported functional outcomes up to 3 months post-stroke. To clarify these conflicting data, we related the acute and 3-month post-stroke levels of s-VEGF to functional outcomes after 3 months and 2 years in a relatively large group of IS patients and evaluated the importance of age, initial IS severity, and the major localization and etiology of IS. We used data from the Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS, N = 492 for the acute time-point 16, 17 ) , and the relative contributions of different mechanisms were evaluated using multivariate regression analyses. In these analyses, we included potential confounders or mediators, such as cardiovascular risk factors, IS severity, and as a marker for brain and systemic inflammation high-sensitivity C-reactive protein (hs-CRP). 18, 19 
| SUBJEC TS AND ME THODS
The design of SAHLSIS has been reported elsewhere. 16, 17, 20 Briefly, patients aged <70 years with first-ever or recurrent acute IS were 
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cerebrovascular diseases, functional outcome, inflammation, ischemic stroke, rehabilitation, stroke severity, strokes, vascular endothelial growth factor randomly selected from population registers to match the sex and average age of the patients. Stroke severity at acute stroke was initially recorded according to the Scandinavian Stroke Scale (SSS), as the maximum score during Days 0-10, and this was transformed into the more frequently used NIHSS according to the validated algorithm: NIHSS = 25.68-0.43 × SSS. 22 As NIHSS showed a skewed distribution, we also performed analyses in which NIHSS was transformed into quintiles (NIHSS-q) as described in the Appendix S1 and in a previous publication. 23 The recordings of hypertension, diabetes mellitus, and smoking had very few missing data-points (Table 1) . 16 More data were lacking for low-density lipoprotein (LDL, mmol/L; N = 75, Table 1 ); the mean of the baseline LDL levels was imputed to have complete LDL datasets when used as a covariate in the regression models. The characteristics of the patients . The Wilcoxon test showed that there was no significant difference in sS-VEGF levels between baseline and 3 mo (P = .24). N/A, Not available. ΔVEGF represents the intra-individual change in s-VEGF from baseline to 3 mo post-IS, which was tested with analysis of variance (ANOVA) against a hypothetical no change population with the same variation and number, and showed no statistical significance (P = .26).
Abbreviations: BMI, body mass index; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; N/A, not available; NIHSS, National Institutes of Health stroke scale; VEGF, vascular endothelial growth factor. a Identical values.
TA B L E 1 Baseline characteristics of the SAHLSIS participants (patients and controls)
and controls have been reported previously 16, 20, 24 (Table 1) . For a more detailed description of the study design, and a description of a minor modification made to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) 25, 26 and major localization Oxford Community Stroke Project (OCSP) subtyping, 27 the reader is directed to the Appendix S1. The study was approved by the Ethics Committee of the University of Gothenburg.
| Biochemical analyses
The s-VEGF concentrations were measured using the commercially available Human Hypoxia Serum/Plasma Assay, MSD® 96-Well MULTI-SPOT® (Meso Scale Diagnostics) according to the instructions of the manufacturer, and using the QuickPlex SQ 120 reader and the Discovery Workbench software from the same company. In order to ensure a reliable analysis, we performed pre-analytical testing of variation and biomarker stability, which demonstrated high biological stability for up to 10 freeze-thaw cycles (data not shown).
The intra-assay coefficient of variation (CV) of the measurements of s-VEGF was relatively low (3.6%). The inter-assay CV was 10.7%. In addition, a few samples (n = 18 for all analyzed samples, including controls) were below the detection limit; these were all set to 50% of the lower limit of the assay. Although the inter-assay variation for s-VEGF was relatively small, we chose to normalize the obtained values in each plate according to the three different quality control samples that were included in the runs.
| Statistical evaluation
Statistical analyses were performed using the SPSS ver. 25 Our main outcome variable was functional outcome, as measured using mRS at 3 months and 2 years after IS. This variable was dichotomized to distinguish good (functional independence; mRS 0-2) from poor (death or functional dependency; mRS 3-6) outcomes. The baseline and 3-month s-VEGF levels were log 10 -transformed due to the marked skewness of the distributions. However, the changes in s-VEGF (ΔVEGF) were retained as original (non-transformed) values.
We used binary logistic regression to calculate the odds ratios (OR) and 95% CI, as well as the corresponding P-values (P-trends) for poor outcome (mRS 3-6) using the logarithmic values of s-VEGF as a continuous variable (showing the OR per 10-fold increase in s-VEGF).
To adjust for potential confounders in the binary logistic regression analyses, we applied age and sex (Model 1), additionally, cardiovascular risk factors (hypertension, smoking, diabetes, and LDL) (Model 2), and finally, initial stroke severity (Model 3a). As stroke severity is related in part to stroke localization (OCSP, 27 ) as well as inflammation (assessed by hs-CRP, 18, 19 ), these parameters were incorporated
into Model 3b and 3c, respectively. When presenting the data, the hs-CRP values were converted into quintiles (q1 = 0-1.24; q2 = 1.25-2.66; q3 = 2.67-4.97; q4 = 4.99-11.8; q5 = 11.9-150 mg/l), whereas hs-CRP was used as continuous covariate in the regression analyses.
Differences that gave P-values < .05 were considered statistically significant.
| RE SULTS

| Baseline data, s-VEGF levels, and stroke characteristics
The baseline characteristics of the patients (N = 492, 36% female) and control subjects are presented in Table 1 . Hypertension, diabetes, and smoking were observed more frequently among the IS patients. Although the baseline s-VEGF was numerically 19% higher in the patients than in the controls, this difference was not significant ( Table 1 ). The 3-month s-VEGF levels were not significantly different from the baseline s-VEGF levels (P = .24, Table 1 ). ΔVEGF, which represents the intra-individual change in s-VEGF from baseline to 3 months post-stroke, tended non-significantly to be reduced (a mean decrease of −21.4 pg/mL, which corresponds to only 4.5%
of the baseline level of s-VEGF, P = .26; Table 1 ). Furthermore, the baseline (r = .09, P = .04) but not the 3-month (r = .01, P = .84) s-VEGF levels correlated with age. However, both the baseline and 3-month s-VEGF levels differed between the age-decade groups, with gradually increasing values until the age range of 40-50 years followed by a plateau phase ( Figure S1A ). The baseline levels of s-VEGF did not differ in relation to the day after stroke onset on which it was sam- The baseline levels of hs-CRP had a weak but significant correlation with the baseline (r = .16, P < .001) and 3-month (r = .12, P = .01) levels of s-VEGF, and with ΔVEGF (r = −.13, P < .001). However, only the baseline s-VEGF differed between the acute hs-CRP quintiles ( Figure S2B ). Baseline s-VEGF was 39.8% higher, and 3-month s-VEGF was 28.9% higher, for the OCSP subtype of TACI compared to LACI, whereas there were no significant differences with regard to TOAST subtype ( Table 2) . The values of ΔVEGF across both OCSP and TOAST subtypes were statistically similar (data not shown). 
| Circulating VEGF levels and functional outcomes after 3 months and 2 years
The clinical data for patients with good or poor functional outcome 2 years after IS are given in Table 3 . We performed binary logistic regression analysis using s-VEGF as a log 10 continuous variable; these analyses showed that the baseline s-VEGF was not associated with poor outcome at either 3 months or 2 years post-IS, regardless of any adjustments made ( Table 4 , upper panels).
ΔVEGF did not show any crude significant associations with functional outcome (not shown).
Next, we analyzed the 3-month level of s-VEGF with respect to functional outcome after 3 months and after 2 years (Table 4 , (Table S1 ).
Finally, as CRP is a marker of bacterial infections (typically at concentrations >10 mg/L) and inflammatory reactions related to the ischemic lesion size (typical range: 1-15 mg/L), 19 we excluded the cases with hs-CRP > 11.9 mg/L (quintile 5), so to assess the im- 
| Methodological considerations
A strength of our study is that the study population (N = 492 for baseline levels and N = 469 for 3-month levels of s-VEGF, respectively) was considerably larger than those used in previous studies of VEGF in IS patients (N = 26, 11 N = 83, 8 and N = 171 9 ). In addition, the follow-up time was 2 years, as compared to 3 months in comparable earlier studies. 8, 9, 11 Subsequently, some studies only investigated the sub-acute temporal profiles of s-VEGF in relation to stroke severity. 6, 7 Patient enrollment in our study was consecutive and carried out at stroke centers in and around the Gothenburg area.
Sweden has one of the highest hospitalization rates for IS in Europe, at around 84%-95%, 29 and the highest rates are found among IS patients <70 years of age. 30 Our relatively young patient population (mean age, 57 years) was well-characterized, further contributing to a high-quality follow-up with low rates of co-morbidity and mortality, as well as few dropouts (eg, missing data were N = 7 for 2-year mRS and N = 23 for 3-month s-VEGF, Figure 1 ). For some of the subanalyses, the low number of events (eg, deaths; N = 22) reduced the statistical power, but we chose to present the HRs for future comparisons. Accordingly, despite a HR of 1.90, the 3-month levels of s-VEGF were not significantly associated with all-cause mortality.
Furthermore, when our IS population was stratified based on major localization (OCSP) 27 and etiology (TOAST), 25 the subgroups were relatively small (N = 37-162). Although most of the ORs for the association between 3-month s-VEGF and 2-year functional outcome were not significant in the stroke subgroup analyses, the ORs were in the same direction as that in the entire cohort (except for the arterial dissection subgroup).
There are also some limitations, which deserve mention. While the inclusion of younger patients has certain advantages, it diminishes the generalizability to elderly IS patients. In addition, the participants were of Caucasian ethnicity and from a distinct geographic area, which might further reduce the generalizability of our findings.
The variability of the first sampling time-point for the subjects (median, Day 4), which prevents the assessment of detailed individual day-by-day changes in s-VEGF levels, is a weakness, as is the lack of radiologic measurements of stroke volumes. However, there is a moderate-to-strong correlation between the baseline score on the NIHSS and stroke lesion volume (r = .51-.71). 31 The patients were enrolled in the period of 1998-2003, when few were treated with thrombolytic agents (only N = 5 in our cohort), and after this period, there have been some alterations in prevention therapies with, for example, extended indications for novel anticoagulants. Finally, although thrombolysis does not increase the level of s-VEGF, 11 it is of note that our study with a low rate of thrombolysis may be more representative of endogenous regulation of s-VEGF than studies with a higher rate of thrombolysis. As CRP is also a marker of bacterial infections (typically at concentrations >10 mg/L) and inflammatory reactions related to IS lesion size (typical range, 1-15 mg/L), 19 it is noteworthy that the exclusion of hs-CRP levels >11.9 mg/L (quintile 5) neither increased nor diminished the magnitude of the associations. This indicates that infections are probably not a confounder for functional outcome with regard to inflammation and s-VEGF levels.
| Previous studies on VEGF and IS
The baseline level of s-VEGF was numerically (19%), but non-significantly (P = .24), higher in the IS patients than in the age-and sex-matched controls, which is partly contrary to the results of previous studies showing higher s-VEGF levels in IS patients than in control subjects. 6, 7 In the study by Slevin et were not shown or not performed. Although thrombolysis was not presented separately with regard to s-VEGF levels, it is noteworthy that a large proportion of the latter study population was derived from patients who were treated at a rehabilitation center after thrombolysis or thrombectomy (77%), and the initial IS was quite severe (median NIHSS score of 17), as compared to the mean NIHSS score of 5.32 in our study. In contrast to these associations, another study (N = 171) presented results comparable to ours, 9
revealing either neutral (atherothrombotic IS) or inverse (cardioembolic) associations between high s-VEGF levels and functional outcome after 3 months. In another study (N = 43) including both IS and intracerebral hemorrhage (ICH), functional data were not reported, but an positive association was observed between 3-month s-VEGF and the radiologic appearance of post-stroke small vessel disease burden, 13 which indirectly would be in some accordance with our results. Thus, our findings, derived from a considerably larger cohort, indicate that a high 3-month level of s-VEGF is associated with a poor 2-year functional outcome.
We did not find any significant associations that withstood multivariate adjustments between s-VEGF levels and the 3-month functional outcome, which was the only functional outcome reported in the previous studies. The association between the 3-month level of s-VEGF and poor 2-year functional outcome remained statistically significant in all the models including adjustment for initial IS severity, and the ORs were rather high at 2.29-2.81 per 10-fold increase in s-VEGF. Finally, for another biomarker that we studied previously, IGF-1, the post-stroke serum level change was associated with functional outcome. 23, 32 In the case of VEGF, when evaluating the change from the acute phase to 3 months post-IS, we found no such pattern.
| Significance of VEGF-local brain and serum VEGF levels
Previous reports on VEGF and experimental stroke have shown two diverging lines of treatment effects; local administration of VEGF within the brain was favorable with neuroprotective and plasticity-promoting effects (for review, see 2 ), whereas systemic administration resulted in adverse or obscure effects. [2] [3] [4] [5] This suggests that the neurobiology of VEGF is complicated; on one hand, it may be beneficial to achieve high local levels of VEGF to enhance plasticity-related recovery, and on the other hand, an unfavorable systemic response in serum associated with inflammation, the latter supported by the positive association in our study between hs-CRP and s-VEGF. Possibly, also the vascular damage on the blood-brain barrier (BBB) caused by the stroke may be associated with increasing VEGF in the penumbra zone, 33 which may reach the circulation via "backward" efflux due to the lack of an intact BBB. This has not been shown in experimental IS, 34 but may be present in the more severe BBB breakdown in tumors. 35 However, the widely accepted possibility is that a molecule or growth factor in the circulation can reach the brain via surpassing an injured BBB, for at least 4 weeks after experimental IS. 34 Note: Baseline and 3-month s-VEGF levels and poor functional outcomes from IS. The odds ratios (OR) per log unit (10-fold) and the corresponding 95% confidence intervals (CI) were calculated by employing binary logistic regression using log 10 s-VEGF as a continuous variable. Models 1-3 are shown with successively added adjustments for age (A), sex (S), traditional cardiovascular covariates (C, see Methods), initial stroke severity (I), major stroke localization according to the Oxford Community Stroke Project (OCSP) classification (Bamford, Sandercock et al 1991) , and high-sensitivity C-reactive protein (hs-CRP).
brain more readily due to BBB dysfunction in IS. Furthermore, there is a need to include control groups, preferably consisting of age-and sex-matched healthy subjects as well as measurements at several time-points to evaluate s-VEGF and its changes in IS, which has not been performed in some previous studies. 6, 7, 10, 12, 13 In contrast, our study has a large sample size, a population-based control group of similar age and gender distribution as the IS patients, and measurements of s-VEGF at two time-points. Therefore, the absence of statistically significant differences in s-VEGF in our study, both when comparing the two time-points and versus the controls, suggests that s-VEGF is not to any major degree dynami- 
| CON CLUS IONS
To the best of our knowledge, this is the first study to present results for VEGF levels in serum and long-term follow-up beyond 3 months with respect to functional outcome in IS patients. We show that s-VEGF is associated with poor functional outcome at 2 years poststroke. The 2-year associations withstood adjustments for age, sex, cardiovascular risk factors, and initial stroke severity. In contrast to the acute baseline level of s-VEGF, the 3-month s-VEGF level appears to be an independent prognostic factor for stroke outcome, although the associations with outcome are linked in part to stroke severity and hs-CRP levels. The present study, having a higher statistical power than previous studies and with more extensive adjustments for relevant covariates, attaches a caveat to the associations between endogenous s-VEGF and functional outcome observed in some of the previous studies. Finally, although the observational nature of our study precludes any conclusion about causality, the results provide support that s-VEGF might be an important factor to target in further research. In further studies, the relationships between VEGF levels in the circulation and CSF with respect to stroke severity and functional outcome could be of special interest.
